Despite aggressive industry efforts over the past 15 years to improve the speed and efficiency of drug development, a new CenterWatch analysis finds no significant gains have been made in shortening median clinical development cycle times.

From the trenches: Sites’ eye view of state of the industry

Ask an experienced clinical researcher how trials have changed over the past few years and you’re likely to hear about the good—more accurate data due to EDC and advanced technologies; the bad—tougher patient recruitment and retention; and the downright ugly—problems getting paid appropriately and on time.

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.